微創醫療(00853.HK)斥8800萬歐元收購Hemovent 助力在急危重症整體解決方案領域發展
格隆匯10月4日丨微創醫療(00853.HK)公吿,公司附屬公司MicroPort Surgical B.V.以8800萬歐元代價自Hemovent股份有限公司現有股東收購其所有已發行股本的收購條件已於近期達成。交易完成後,Hemovent將成為集團全資附屬公司。另外,倘Hemovent於交割日期起計5年內達到產品開發的若干開發里程碑及條件,集團將向賣方支付額外金額,最高達3500萬歐元。
Hemovent成立於2013年,為一間從事創新型體外生命支持系統的醫療器械公司。Hemovent的主要產品包括MOBYBOX,已獲得CE認證,是第一款將血液循環與氣體交換整合為一體的體外膜式氧合系統(ECMO)。
集團致力為全球患者提供心外科和危重症監護的全面解決方案。本次收購可以發揮雙方在行業資源、行業經驗以及產品研發方面的優勢,加快相關產品的研發、生產及商業化進程,助力集團在急危重症整體解決方案領域的發展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.